SDC-1801 mainly focuses on treating psoriasis. Credit: Martin Trotter/ Flickr (Creative Commons).

Sareum Holdings has received approval for its application submitted for initiation of a Phase I clinical trial of SDC-1801 in Australia.

Being developed as a potential new treatment for various autoimmune diseases, SDC-1801 mainly focuses on treating psoriasis, an autoimmune condition that affects the skin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study will examine the pharmacokinetic properties along with safety of an oral formulation of SDC-1801 in ascending doses given to healthy participants.

Upon receiving satisfactory safety data from the study, the company plans to initiate a Phase Ib trial next year in patients with psoriasis.

A TYK2/JAK1 inhibitor, SDC-1801 has strong clinical validation in treating psoriasis and psoriatic arthritis and showed benefits in maintaining a healthy immune system.

See Also:

Sareum CEO Dr Tim Mitchell said: “The approval of this application is a very important step for Sareum and we are now ready to bring our lead asset into clinical development. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are very excited about the potential of SDC-1801, which we believe could offer superior efficacy compared to other currently-available small molecules for psoriasis and which has demonstrated a good safety profile in preclinical studies.

“We look forward to initiating our Phase I trial in the coming weeks.”

The application has been acknowledged by Australia’s medicines regulator, the Therapeutic Goods Administration, and approved by the Human Research Ethics Committee.